43 completed, 14 recruiting, 8 terminated, 8 unknown. 87 Phase 1, 31 Phase 2.
Follow Disease: new trials by email Literature Review of Disease trials Research Report on Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-GRIP B in Patients With Acute Myocarditis 64Cu-GRIP B is a radiolabeled peptide tracer, a copper-64 isotope bound to a peptide designed to target extracellular Granzyme B - Acute Myocarditis | Phase 1 | Not yet recruiting | Javid Moslehi, MD | 10 | 2027-01-01 | 2026-10-15 |
| Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC) [68Ga]Ga DOTA-5G - Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Luminance Biosciences Inc | 10 | 2026-11-15 | 2026-11-04 |
| S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas S-Adenosylmethionine (SAMe) - Colorectal Cancer (Diagnosis), Adenoma | Phase 1 | Not yet recruiting | Jun Gong, MD | 18 | 2026-11-01 | 2026-08-04 |
| Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe - Asthma (Diagnosis), Persistent Asthma | Phase 1 | Not yet recruiting | University of North Carolina, Chapel Hill | 60 | 2026-11-01 | 2026-07-15 |
| A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma SKB575, Placebo - Asthma (Diagnosis) | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 36 | 2026-08-25 | 2026-09-10 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-11-06 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| ADO-5030 in Bronchoconstriction Challenge, Phase 1b ADO-5030 - Asthma (Diagnosis) | Phase 1 | Not yet recruiting | Adovate | 36 | 2026-01-01 | 2026-01-22 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC ABT-301, Tislelizumab, Bevacizumab (Avastin) - Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Anbogen Therapeutics, Inc. | 66 | 2025-11-01 | 2025-11-24 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe Prostate biopsy - Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Johns Hopkins University | 60 | 2025-09-23 | 2026-11-06 |
| Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC RYZ811, RYZ801 - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | RayzeBio, Inc. | 590 | 2025-09-05 | 2026-09-28 |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy - Prostate Cancer, Prostate Cancer (Diagnosis) | Phase 1 | Recruiting | Thomas Hope | 45 | 2025-07-08 | 2026-08-28 |
| Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy GOLCADOMIDE, Nivolumab - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | University of Pittsburgh | 2025-06-30 | 2026-04-13 | |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| Precision Antibiotic Dosing for Appendectomy Cefoxitin - Appendicitis (Diagnosis) | Phase 1 | Completed | University of Michigan | 53 | 2025-02-28 | 2026-11-02 |
| Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults J4, Placebo - Alzheimer Disease | Phase 1 | Recruiting | Academia Sinica, Taiwan | 76 | 2025-02-14 | 2026-01-06 |
| Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases EBV immunological agent - CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs | Phase 1 | Not yet recruiting | West China Hospital | 27 | 2024-10-01 | 2024-10-30 |
Showing 20 of 87. Sign in to see all of them.
Neoplasms (9) · Multiple Myeloma (6) · Breast Neoplasms (5) · Colorectal Neoplasms (5) · Guillain-Barre Syndrome (5) · Prostatic Neoplasms (5) · Syndrome (5) · Neoplasm Metastasis (4) · Pancreatic Neoplasms (4) · Recurrence (4) · Asthma (3) · Hematologic Diseases (3) · Leukemia (3) · Lung Neoplasms (3)
Pathological Conditions, Signs and Symptoms (87) · Pathologic Processes (86) · Neoplasms (30) · Neoplasms by Site (27) · Immune System Diseases (23) · Neoplasms by Histologic Type (23) · Hemic and Lymphatic Diseases (18) · Nervous System Diseases (15) · Disease Attributes (14) · Digestive System Diseases (13) · Hematologic Diseases (13) · Immunoproliferative Disorders (13) · Respiratory Tract Diseases (13) · Lymphoproliferative Disorders (12) · Cardiovascular Diseases (11)
Cyclophosphamide (4) · Dexamethasone (4) · Vaccines (3) · Bupivacaine (2) · Exchange Transfusion, Whole Blood (2) · Exercise (2) · Sirolimus (2) · Vancomycin (2) · Whole-Body Irradiation (2) · carfilzomib (2) · (225)Ac-PSMA-617 (1) · 130-nm albumin-bound paclitaxel (1) · 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1) · 5,10-dihydro-5-methylphenazine (1) · Albumin-Bound Paclitaxel (1)
Novartis Vaccines (4) · Anaveon AG (3) · University of Florida (3) · Columbia University (2) · Dana-Farber Cancer Institute (2) · European Myeloma Network B.V. (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis (2) · University of Michigan (2) · Academia Sinica, Taiwan (1) · Adovate (1) · Anbogen Therapeutics, Inc. (1) · Andrew Hendifar, MD (1)
United States (48) · China (8) · Switzerland (8) · Australia (6) · Canada (4) · Italy (4) · Spain (4) · United Kingdom (4) · Denmark (3) · France (3) · Taiwan (3) · Germany (2) · Argentina (1) · Belgium (1) · Israel (1)
Eduard Gasal, MD (3) · Andrew Hendifar, MD (1) · Annick Desjardins, MD (1) · Bobby Tajudeen, MD (1) · Braden Kuo, MD (1) · Brian L Edlow, MD (1) · Cameron R Smith (1) · Claes H Dohlman, MD, PhD (1) · Clarissa Foy, NP (1) · Constance Dorian, BS Biology (1) · Douglas Gladstone, MD (1)
PMID 11435294, PMID 12393655, PMID 12599068, PMID 19236801, PMID 20498651, PMID 20593018, PMID 21271600, PMID 21361747, PMID 23098171, PMID 23255493, PMID 23737188, PMID 24874401, PMID 25137523, PMID 25540170, PMID 25703058, PMID 25735952, PMID 25926600, PMID 26205347, PMID 26452438, PMID 26719678, PMID 26888961, PMID 26928074, PMID 27404453, PMID 28210942, PMID 28922579, PMID 29489633, PMID 30149366, PMID 30201848, PMID 30220407, PMID 31221778, PMID 32107329, PMID 32245502, PMID 32373649, PMID 32598475, PMID 34552486, PMID 35022322, PMID 36056179, PMID 36556158, PMID 36969150, PMID 37853118, PMID 38243906, PMID 38853689, PMID 40483726, PMID 41679299
2014 (2), 2016 (1), DP2HD101400 (1), K01AA026005 (1), P50NS020023 (1), R01AA015419 (1), R01CA303859 (1), R01NR012237 (1), R21AG064282 (1), R21CA267584 (1), R34HL179910 (1), U54AI150225 (1)